Fermenta Biotech Ltd
Fermenta Biotech Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹95Cr
- +67% YoY
- Net profit
- ₹11Cr
- Q2 FY24: −₹29 Cr
- Margin
- 19.76%
- +44.2 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2-FY25 Operational Revenue: - Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) - Consolidated: INR 950 Mn, a 67.0% YoY increase (from INR 569 Mn in Q2-FY24) (P Quarterly Consolidated Financials (Q2-FY25 vs Q2-FY24): - Operational Revenue: INR 950 Mn, up 67.0% YoY - Operational EBITDA: INR 187 Mn (margin 19.68%), compared to -139 Mn (negative margin
From Fermenta Biotech Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2-FY25 Operational Revenue:
- Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9)
- Consolidated: INR 950 Mn, a 67.0% YoY increase (from INR 569 Mn in Q2-FY24) (Page 11)
- Volume Highlights (Page 7):
- Vitamin D3 for Human Nutrition volumes increased by 62% YoY in Q2-FY25
- Animal Feed volumes increased by 137% YoY in Q2-FY25
- Animal Feed average prices were 3 times higher in Q2-FY25 vs Q2-FY24
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Fermenta Biotech Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 95 | 57 | +67% | 78 | +21.6% |
| Operating profit (EBITDA) | 19 | -14 | — | 1 | +2247.5% |
| Operating margin | 19.76% | -24.44% | +44.2 pp | 1.02% | +18.7 pp |
| Profit before tax | 12 | -29 | — | -6 | — |
| Net profit (PAT) | 11 | -29 | — | -6 | — |
| EPS (₹) | 3.87 | -9.70 | — | -1.98 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q2 FY25 results?
Q2-FY25 Operational Revenue: - Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) - Consolidated: INR 950 Mn, a 67.0% YoY increase (from INR 569 Mn in Q2-FY24) (P Quarterly Consolidated Financials (Q2-FY25 vs Q2-FY24): - Operational Revenue: INR 950 Mn, up 67.0% YoY - Operational EBITDA: INR 187 Mn (margin 19.68%), compared to -139 Mn (negative margin
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.